论文部分内容阅读
目的:探讨孟鲁司特在小儿哮喘中的临床治疗效果。方法:选择2012年1月-2013年1月我院确诊为哮喘的92例患儿作为本次研究对象,随机将其分为两组,对照组46例给予常规对症治疗,观察组46例在常规治疗基础上加用孟鲁司特,观察比较两组的临床疗效。结果:观察组治疗后总有效率为95.65%,对照组的总有效率80.43%,两组比较差异具有统计学意义(p<0.05);观察组的咳嗽消失时间、喘息消失时间和肺部体征消失时间均明显好于对照组(p<0.05)。结论:孟鲁司特提高了小儿哮喘的临床疗效,快速缓解了临床症状,值得临床推广应用。
Objective: To investigate the clinical efficacy of montelukast in pediatric asthma. Methods: A total of 92 children diagnosed with asthma in our hospital from January 2012 to January 2013 were randomly divided into two groups. 46 patients in the control group were given conventional symptomatic treatment and 46 patients in the observation group On the basis of routine therapy plus montelukast, the clinical efficacy was observed and compared between the two groups. Results: The total effective rate was 95.65% in the observation group and 80.43% in the control group, the difference between the two groups was statistically significant (p <0.05); the cough disappearing time, wheezing disappearance time and lung signs Disappear time were significantly better than the control group (p <0.05). Conclusion: Montelukast improves the clinical efficacy of pediatric asthma and quickly relieves the clinical symptoms, which is worthy of clinical application.